[关键词]
[摘要]
目的 探究门冬胰岛素在治疗糖尿病肾病(DN)中的疗效及其对患者超氧化物歧化酶(SOD)及丙二醛(MDA)的影响。方法 选取2015年1月-2016年1月于青海省交通医院收治的96例DN患者,按照随机数字表法均分为实验组和对照组,每组48例,对照组患者给予皮下注射合成人胰岛素进行治疗,实验组给予皮下注射门冬胰岛素,在治疗1、3、5 d测定两组空腹血糖(FPG)及餐后2 h血糖(2hPG)并对比,在治疗第5天对两组24 h尿微量白蛋白排泄率(UAER)及内生肌酐清除率(Ccr)进行测定对比,而后对两组治疗前后SOD及MDA水平进行测定并对比。结果 经治疗,两组在治疗1、3、5 d后的FPG及2hPG均低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);实验组在治疗第3、5天时的FPG及2hPG均低于对照组,差异具有统计学意义(P<0.05)。治疗5 d后测量结果显示,两组UAER水平均明显降低,Ccr水平明显升高,同组治疗前后比较差异有统计学意义(P<0.05);实验组UAER水平显著低于对照组,Ccr水平高于对照组,两组差异具有统计学意义(P<0.05)。治疗前两组SOD及MDA水平差异不具有统计学意义;治疗后,两组SOD水平均显著升高,MDA水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);实验组的SOD水平显著高于对照组,MDA水平显著低于对照组,组间差异有统计学意义(P<0.05)。结论 门冬胰岛素在治疗糖尿病肾病方面效果肯定,同时该药能够提高糖尿病肾病患者SOD、降低MDA水平,对患者的治疗具有积极意义。
[Key word]
[Abstract]
Objective To investigate the efficacy of insulin aspart in the treatment of diabetic nephropathy (DN) and its effects on superoxide dismutase (SOD) and malondialdehyde (MDA). Methods 96 patients with DN who were admitted to our hospital from January 2015 to January 2016 were randomly divided into experimental group and control group according to random number table method, 48 cases in each group. Patients in control group were given hypodermic injection of synthetic insulin The rats in experimental group were injected subcutaneously with insulin aspart, the fasting blood glucose (FPG) and 2h postprandial blood glucose (2hPG) were measured at 1, 3 and 5 days after treatment. The blood glucose of 24 h urine microalbumin (UAER) and endogenous creatinine clearance (Ccr) were measured and compared, and then the two groups before and after treatment SOD and MDA levels were measured and compared. Results The 1, 3, 5 d FPG and 2 h PG in the experimental group were lower than those in the control group after treatment (P<0.05), but there was no significant difference between the two groups before treatment. The level of UAER in the 5th day after treatment was significantly lower than that in the control group, and the Ccr was higher than that in the control group (P<0.05). There was no significant difference in SOD and MDA levels between the two groups before treatment. The SOD level in the 5th day after treatment was significantly higher than that in the control group, the MDA level was significantly lower than that in the control group (P<0.05). Conclusions Aspart insulin in the treatment of diabetic nephropathy is worthy of affirmation. At the same time, this medicine can improve the level of SOD in patients with diabetic nephropathy, and has positive significance for the treatment of patients.
[中图分类号]
[基金项目]